NEW YORK (AP) -- Genzyme, owned by French drugmaker Sanofi, said Monday that regulators in Argentina approved its once-per-day multiple sclerosis pill Aubagio.
Aubagio is designed to treat flare-ups of the neurological disorder. The drug received U.S. approval in September and reached the market in October. Genzyme said sales in the fourth quarter totaled 7 million euros ($9.3 million). Australian regulators approved Aubagio in November.
A European Union advisory panel recommended in March that Aubagio be approved, but the drug has not yet received full marketing approval.
Sanofi shares rose 15 cents to $50.81 in midday trading.